What are the clinical presentation, diagnostic approach, and recommended treatment for Q fever?

Q Fever: Clinical Presentation, Diagnosis, and Treatment

Clinical Presentation

Acute Q Fever

Acute Q fever typically presents as a nonspecific flu-like illness with fever, headache, rigors, weight loss, myalgia, and arthralgia, though pneumonia and hepatitis are the primary clinical manifestations. 1

• Most cases are mild, though severe presentations occur 2
• Chest radiograph abnormalities appear in >96% of patients, showing segmental or lobar consolidation (unilateral or bilateral) 1
• Radiographic patterns are nonspecific and cannot differentiate Q fever from other community-acquired pneumonias 1
• Children often present with gastrointestinal symptoms and rash rather than typical respiratory findings 3
• Approximately 20 days typically elapse between exposure and symptom onset 2

Chronic Q Fever

Endocarditis and vascular infections (aneurysms, grafts) are the most common and life-threatening forms of chronic Q fever, which is generally fatal if untreated. 1

• Chronic Q fever develops in patients infected for >6 months 2
• High-risk patients include those with preexisting valvular heart disease, vascular grafts, arterial aneurysms, pregnancy, or immunosuppression 1
• Symptoms include prolonged fever, chills, fatigue, night sweats, and shortness of breath 2
• In children, osteomyelitis is one of the most common chronic manifestations, contrasting with adults 1

Pregnancy-Related Complications

Women infected during pregnancy face increased risk for miscarriage (especially first trimester), preterm delivery, and recrudescent infection in subsequent pregnancies. 1

• Untreated first-trimester infection more likely results in miscarriage; later infection causes premature delivery 1
• Women should avoid pregnancy for at least 1 month after diagnosis and treatment 1

Diagnostic Approach

Laboratory Testing Strategy

Do not wait for laboratory results to begin treatment and do not stop treatment based on negative acute serology results, as seroconversion is often delayed. 1

Acute Phase Testing

• PCR of whole blood or serum provides rapid results during the first 2 weeks after symptom onset but before antibiotic administration 1
• Serology (IFA) is negative during early acute illness; most patients seroconvert by the third week 1
• A fourfold increase in phase II IgG or IgM antibody titer by IFA in paired acute and convalescent samples is the diagnostic gold standard 1
• A single convalescent phase II IgG antibody titer ≥1:128 by IFA supports diagnosis, though paired samples have higher sensitivity and specificity 1

Chronic Q Fever Diagnosis

Chronic Q fever requires both laboratory evidence (phase I IgG antibody titer ≥1:1024) AND an identifiable persistent infection focus such as endocarditis. 1

• Detection of DNA by PCR in clinical specimens (heart valve, serum) 1
• Immunohistochemistry staining of organism in tissue 1
• Isolation of Coxiella burnetii by culture 1
• Critical caveat: Elevated phase I IgG titers alone without clinical evidence should NOT trigger treatment, as serologic profiles of chronic Q fever can develop and regress without true chronic infection 1

Imaging for Chronic Disease

• Echocardiography and PET/CT scanning should be performed when nonspecific clinical findings accompany laboratory evidence to search for infection foci 1

Treatment Recommendations

Acute Q Fever

Doxycycline 100 mg twice daily for 14 days is the treatment of choice for adults and children ≥8 years with acute Q fever. 1

Adults

• Doxycycline 100 mg orally twice daily for 14 days 1
• Take with food to avoid stomach upset, but avoid dairy products within 2 hours 1

Children ≥8 Years

• Doxycycline 2.2 mg/kg per dose twice daily for 14 days (maximum 100 mg per dose) 1

Children <8 Years

• High-risk criteria: Doxycycline 2.2 mg/kg per dose twice daily for 14 days (maximum 100 mg per dose) 1
• Mild/uncomplicated illness: Doxycycline 2.2 mg/kg per dose twice daily for 5 days; if fever persists past 5 days, switch to trimethoprim/sulfamethoxazole 4-20 mg/kg twice daily for 14 days (maximum 800 mg per dose) 1

Pregnant Women

• Trimethoprim/sulfamethoxazole 160 mg/800 mg twice daily throughout pregnancy 1

Chronic Q Fever

Chronic Q fever requires combination therapy with doxycycline 100 mg twice daily PLUS hydroxychloroquine 200 mg three times daily for prolonged duration. 1

Treatment Duration

• Native valve endocarditis: Minimum 18 months 1
• Prosthetic valve endocarditis: Minimum 24 months 1
• Vascular infections (aneurysms, grafts): 18-24 months; early surgical intervention improves survival 1
• Postpartum women with serologic profile for chronic Q fever: 12 months 1

Monitoring During Treatment

Patients require monthly serologic testing (phase I and II IgG and IgM) and monthly clinical evaluations throughout treatment. 1

• Monitor hydroxychloroquine plasma levels (maintain 0.8-1.2 μg/mL) and doxycycline levels (maintain ≥5 μg/mL) if inadequate treatment response 1
• Baseline ophthalmologic examination before treatment and every 6 months thereafter due to retinal toxicity risk from hydroxychloroquine 1
• Hydroxychloroquine is contraindicated in G6PD deficiency and retinal/visual field deficits 1
• Both medications cause photosensitivity 1

Treatment Endpoint Criteria

• Treatment can be discontinued when serologic monitoring demonstrates fourfold decrease in phase I IgG with complete disappearance of phase II IgM and clinical recovery 1
• Patients treated appropriately for ≥18 months who have recovered clinically but maintain phase I IgG ≥1:1024 may not benefit from continued treatment 1
• Continue twice yearly serologic monitoring for minimum 5 years after treatment to detect potential relapse 1

Post-Treatment Surveillance

Standard Risk Patients

• Repeat clinical assessment and serology at approximately 6 months 1
• If no serologic or clinical progression, monitoring can be discontinued or reduced 1

High-Risk Patients (Cardiovascular Risk Factors)

• Serologic and clinical monitoring at 3,6,12,18, and 24 months 1
• High-risk includes heart valve defects, vascular grafts, aneurysms, or pregnancy at time of acute infection 1
• After 2 years without phase I IgG increase ≥1:1024 and no clinical progression, monitoring may be reduced 1
• Lifelong vigilance required: Patients with valvular defects remain at high risk for chronic Q fever throughout life 1

Key Clinical Pitfalls

• Never delay treatment waiting for serologic confirmation, as acute serology is often negative early in illness 1
• Do not diagnose chronic Q fever based on elevated titers alone without clinical evidence of organ involvement 1
• Prophylactic antimicrobials are NOT recommended after known or potential exposure before symptom onset 1
• Q fever should be considered even in patients without occupational risk or livestock contact, as 60% of U.S. cases occur without reported livestock exposure 1
• Transmission can occur over long distances via wind-borne aerosols; urban outbreaks without direct animal contact have been documented 1, 4